Date: 2016-03-03
Type of information: Series B financing round
Company: Autolus (UK)
Investors: Woodford Investment Management (UK) Perceptive Bioscience Investments (UK)
Amount: £40 million
Funding type: series B financing round
Planned used:
- Autolus is founded upon the work of Dr Martin Pule, an academic clinical haematologist at the UCL Cancer Institute and NIHR University College London Hospitals Biomedical Research Centre and a thought-leader in T-cell engineering. The company is developing engineered T-cell products based on its proprietary targets, constructs and technologies.
- The funds will enable Autolus to develop its proprietary pipeline of engineered T-cell products, and to further implement its industry-leading platform of T-cell programming technologies. In parallel with the financing, Autolus' technology platform was enhanced by a licence to additional technologies from UCL Business, UCL’s (University College London) technology transfer company.
Others:
- • On March 3, 2016, Autolus announced that it has raised £40 million of new capital in a Series B financing round. Woodford Investment Management and Perceptive Bioscience Investments participated in the new investment, which augments the previous £30 million Seed and Series A investment from founding investor Syncona. In association with the financing, Dr Joe Anderson, Chief Executive Officer of Perceptive Bioscience, has joined the board of directors of Autolus.
Therapeutic area: Cancer - Oncology
Is general: Yes
